Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long‐Term Real‐World Study

Abstract

Complete treatment discontinuation after MSE in MG carries substantial relapse risk. Individualized discontinuation decisions incorporating younger onset age, prior rituximab use, adequate treatment and consolidation duration may optimize outcomes.